Introduction. In the Republic of Serbia, pregabalin was marketed for the
first time in 2006. Although the abuse of pregabalin has not been a common
topic in the literature so far, it is often seen in everyday practice. Also,
it seems that it is more common among addicts. Case outline. Mr. D. is a
41-year-old male patient, a perennial polytoxicomaniac on buprenorphine
substitution therapy. He began using pregabalin because it caused euphoria
and elevated mood, in daily doses which varies between 1050-2100 mg. The
highest daily dose was 4200 mg. At the time he was admitted to the hospital
for pregabalin detoxification, he met the general criteria for addiction
syndrome. On admission, the patient was tense, anxious, irritable, drenched
in sweat, and had insomnia. With an adequate dose of buprenorphine, the
patient continued to complain about the reduction of the pregabalin dose and
insisted on adjusting the dose. Shortly he was discharged from hospital at
his personal request. After a month, during the check-up examination, he was
diagnosed with a relapse of pregabalin use. He was readmitted to the
hospital for detoxification treatment, the pregabalin dose was gradually
reduced by 100 mg per week. After that the patient went to therapeutic
community to continue treatment. Conclusion. This case indicates that
practitioners have to be cautious when prescribing pregabalin to people
prone to addiction. Further research is needed to identify risk factors for
the development of pregabalin abuse syndrome, as well as to create clear
guidelines for the treatment of abstinence syndrome.